Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Madrigal Pharmaceuticals gains FDA approval for NASH medicine Rezdiffra

Madrigal Pharmaceuticals achieved FDA approval for Rezdiffra, focusing on market leadership and patient services.
Sales expected to be back-end loaded in 2024, with varying prescription dynamics and affordability considerations.
Company confident in revenue consensus but hasn't provided specific numbers, creating uncertainty for investors.
Emphasis on high unmet need, early positive feedback, and comprehensive patient support services.

Madrigal Pharmaceuticals excels in Q2 with Rezdiffra launch success

Madrigal Pharmaceuticals demonstrated strong financial performance and market acceptance of Rezdiffra in Q2 2024.
The company faces challenges in educating stakeholders and managing operational aspects of expansion.
Opportunities lie in global expansion, new market segments, and continued growth in sales and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT04951219). MAESTRO-NAFLD-1 is an ongoing 52-week ~1200 patient Phase 3 non-invasive, multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease (NAFLD), presumed NASH. The study is due to complete later this year with measures of safety and efficacy including reduction in imaging and biomarker measures of NASH, as well as the lowering of LDL-cholesterol and other atherogenic lipids.

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH coupled with safety data from MAESTRO-NAFLD-1, an additional large Phase 3 study, are expected to support the planned Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the US Food and Drug Administration (FDA). Madrigal will continue to enroll additional patients beyond those required for accelerated approval to provide for the clinical outcomes portion of the MAESTRO-NASH Phase 3 clinical trial of resmetirom.

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

CONSHOHOCKEN, Pa., June 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing Phase 3 MAESTRO-NAFLD-1 study of resmetirom at the European Association for the Study of the Liver Annual Meeting, The International Liver Congress™ 2021, being held virtually, June 23-26, 2021. The data continue to position resmetirom as a promising treatment option for nonalcoholic steatohepatitis (NASH) patients.

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021

American Woodmark

Arena Pharmaceuticals

Atreca

Cannae Hlds

Dominion Energy

ESCO Technologies

FutureFuel

Heartland Express

Intelligent Systems

Kiniksa Pharmaceuticals Ltd

Kura Oncology

NewMarket

PG&E

Premier

SelectQuote

Theravance Biopharma

Invesco DB US Dollar Index Bullish Fund

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March.

20 Short Ideas With Super-Weak Momentum

WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET.

Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Alex Howarth has joined Madrigal as Chief Financial Officer.

Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer

WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights.

Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights

The Phase 2 data has been excellent while the company is most likely to present strong data for its Phase 3 MAESTRO-NAFLD-1 trial in late 2021.

Madrigal Pharmaceuticals: Leading The NASH Innovation

WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights.

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

Ligand Pharmaceuticals

Nektar Therapeutics

The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.

Gamestopping Biopharma: These Three Stocks May See A Short Squeeze Soon

In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio, Texas, and Visiting Professor of Hepatology, Oxford University, and Principal Investigator of the MAESTRO studies, will make an oral presentation today at 4:30 PM ET at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting, November 2020 accessible via the Product Theaters and Satellite Symposium page. Dr. Harrison's presentation, based on data from studies with MGL-3196 (resmetirom), will also highlight key insights from three posters, which are available to registered attendees on The Liver Meeting Digital Experience™ website throughout the four-day meeting. Resmetirom is the first orally administered, small-molecule, liver-directed, truly β-selective thyroid hormone receptor (THR) agonist and is currently in Phase 3 development for the treatment of NASH patients both with biopsy-confirmed fibrosis stage 2-3 (ClinicalTrials.gov NCT03900429) and in presumed NASH subjects diagnosed non-invasively (ClinicalTrials.gov/NCT04197479).

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-W

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights.

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

Axsome Therapeutics

Nikola

Tilray Brands

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared first on InvestorPlace.

Small-Cap Stocks Have Led Every Bull Market for Decades

CONSHOHOCKEN, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters and an oral presentation of these data will be presented at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020. Resmetirom is the first orally administered, small-molecule, liver-directed, truly β-selective thyroid hormone receptor (THR) agonist and is currently in Phase 3 development for the treatment of NASH patients both with biopsy-confirmed fibrosis stage 2-3 (ClinicalTrials.go v NCT03900429) and in presumed NASH subjects diagnosed non-invasively (ClinicalTrials.g o v/NC T 04197479).

Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 W

CONSHOHOCKEN, Pa., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments. Resmetirom is the first orally administered, small-molecule, liver-directed, truly β-selective thyroid hormone receptor (THR) agonist currently in Phase 3 development for the treatment of NASH patients with fibrosis stage 2-3 ( ClinicalTrials.gov NCT03900429   and   ClinicalTrials.gov/NCT04197479 ).

Madrigal Pharmaceuticals Exceeds Target Enrollment  in Phase 3 MAESTRO NAFLD-1 Trial

CONSHOHOCKEN, Pa., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data from its Phase 2 NASH study with MGL-3196 (resmetirom) will be presented. Resmetirom is currently in Phase 3 development for the treatment of NASH patients with stage 2-3 fibrosis ( ClinicalTrials.gov NCT03900429   and   ClinicalTrials.gov/NCT04197479 ).

Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

CONSHOHOCKEN, Pa., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:

Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

Intercept Pharma

These two companies are going after the same target, but which one should you bet on today?

Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals

Madrigal Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level.
The post Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating

Bristol-Myers

Vertex Pharmaceuticals

They have one big thing in common: great growth prospects.

3 Top Biotech Stocks to Buy in June

Invacare

Moderna

Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic.

Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction

Madrigal: A Stellar Stock For This Coronavirus Bear Market

News for Madrigal Pharmaceuticals Stock (MDGL)